Weight & Metabolism · commonly explored around metabolism and appetite
Semaglutide
Semaglutide is the GLP-1 medicine behind Wegovy and Ozempic. It turns down appetite and steadies blood sugar, with about 15% average weight loss in its main weight trial.
Informational profile
No verified OnimaChain inventory for this profile.
Also known as Ozempic · Wegovy · Rybelsus · NN9535
Mapped targets
- Sequence
- HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG
- Length
- 31 residues
- MW
- —
- Product tags
- glp 1r · incretin analogue · lipidated
- Checked sources
- No checked source added yet
- Structure provenance
- Rendered from deposited C-alpha coordinates · RCSB PDB 7KI0 chain P; any unresolved tail is modeled
31 residues with Aib at residue 2 and a C18 fatty-diacid tether on Lys20 (GLP-1 positions 8 and 26). Deposited receptor-bound structures resolve the helical core.
See the simple guide ↓Video intro
Semaglutide in ten seconds.
Coming soon.
Meet Semaglutide
The short version, before the deep dive.
Semaglutide is the GLP-1 medicine behind Wegovy and Ozempic. It turns down appetite and steadies blood sugar, with about 15% average weight loss in its main weight trial.
PulseChain
What’s new with Semaglutide
Section B
The quick read
Section C
Research at a glance
A simple picture of the sources we have checked. More color means more records in that category—not that the product works better.
We haven’t added a checked source for this yet.
This picture fills in as we add checked studies for this product.
Section D
What the sources looked at
These topics come only from sources in our record. We do not add a topic just because it is popular online.
No topics yet
Topics show up here once we have checked studies for this product and sorted them.
Section E
Why people look it up
A plain-language starting point. This is not a promise that the product will cause a result.
metabolism and appetite
See Semaglutide beside similar names.
The Portal of Tides lets you switch between a constellation, connection view, checked-source timeline, and topic map. It uses the products already in our collection—no fake customer counts.
Section F
What the record can tell us
A product page can show what was studied. It cannot promise what will happen to a person.
What we can show
No source topic has been added yet.
What we cannot promise
A lab result, animal study, online story, or product page cannot tell you what will happen to you. That question needs qualified medical guidance.
Section G
Claims people make
The big claims tied to this product. Open one to see where it came from and how it spread.
No claims tracked for this product yet
We only add a claim once we can point to where it started, or say clearly that we could not find out.
Section H
How far it has been tested
From cells in a dish, to mice, rats, bigger animals, people, proper trials, and finally regulator approval. The light stops where the checked studies stop.
We have not mapped how far any result has been tested yet.
Section I
How many separate teams
Ten papers from one lab are not ten separate confirmations.
Not checked yet
We only count teams from studies we have confirmed.
Section J
What doesn’t fit?
If a study disagrees, it goes here. We do not hide it.
No study we have checked pushes back yet
Studies that found nothing, disagree, or criticize the method will show up here once we add them. A study that only partly agrees is not the same as one that disagrees.
Section K
Timeline
What happened and when. Studies in one lane, real-world reports in another.
Research
0 events
No dated research update is indexed for this selection.
Trials
0 events
No trial milestones are indexed to this exact record yet.
Regulatory
0 events
No regulator decisions listed yet.
Real-world reports
0 events
No real-world reports yet — social platforms are not connected.
Section L
Sources
Every study we used. Only studies we confirmed on PubMed are shown as sources. Where a drug is FDA-approved, its official label sits beside them — that is an approval, not a sales pitch.
FDA application
Ozempic (semaglutide) — Drugs@FDA application overview
NDA 209637 · retrieved 2026-09-21
FDA-approved (2017) as Ozempic for type 2 diabetes. The current DailyMed label lists it as a GLP-1 receptor agonist used with diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Approved uses are brand- and indication-specific. Research-use vials on this site are not those prescription products.
Open source ↗DailyMed index
Ozempic (semaglutide) — DailyMed label index
DailyMed query OZEMPIC · retrieved 2026-09-21
OZEMPIC (semaglutide) injection, for subcutaneous use. Initial U.S. approval: 2017. Boxed warning for rodent thyroid C-cell tumors; human relevance unknown.
Open source ↗FDA application
Wegovy (semaglutide) — Drugs@FDA application overview
NDA 215256 · retrieved 2026-09-21
FDA-approved (2021) as Wegovy, a separate semaglutide brand for chronic weight management in eligible patients — not interchangeable with research-use material.
Open source ↗We have not added PubMed studies for this product yet. The official labels above are the sources for now.
The building blocks, one by one
| # | Code | Residue | Class | Chirality | Features |
|---|---|---|---|---|---|
| 1 | H | Histidine | positive | L | |
| 2 | Aib | α-Aminoisobutyric acid | hydrophobic | L | Aib |
| 3 | E | Glutamate | negative | L | |
| 4 | G | Glycine | special | L | flexible |
| 5 | T | Threonine | polar | L | |
| 6 | F | Phenylalanine | hydrophobic | L | |
| 7 | T | Threonine | polar | L | |
| 8 | S | Serine | polar | L | |
| 9 | D | Aspartate | negative | L | |
| 10 | V | Valine | hydrophobic | L | |
| 11 | S | Serine | polar | L | |
| 12 | S | Serine | polar | L | |
| 13 | Y | Tyrosine | polar | L | |
| 14 | L | Leucine | hydrophobic | L | |
| 15 | E | Glutamate | negative | L | |
| 16 | G | Glycine | special | L | flexible |
| 17 | Q | Glutamine | polar | L | |
| 18 | A | Alanine | hydrophobic | L | |
| 19 | A | Alanine | hydrophobic | L | |
| 20 | K | Lysine | positive | L | Acyl tether |
| 21 | E | Glutamate | negative | L | |
| 22 | F | Phenylalanine | hydrophobic | L | |
| 23 | I | Isoleucine | hydrophobic | L | |
| 24 | A | Alanine | hydrophobic | L | |
| 25 | W | Tryptophan | hydrophobic | L | |
| 26 | L | Leucine | hydrophobic | L | |
| 27 | V | Valine | hydrophobic | L | |
| 28 | R | Arginine | positive | L | |
| 29 | G | Glycine | special | L | flexible |
| 30 | R | Arginine | positive | L | |
| 31 | G | Glycine | special | L | flexible |